Emma Craythorne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emma Craythorne has a total of 201 co-authors. Here are the top co-authors by number of shared publications:
R. Mallipeddi
St John's Institute of Dermatology, King's College London, London, SE1 9RT, UK
9 shared publications- Faisal R. Ali
School of Medicine and Dentistry, University of Lancashire, Preston, UK
6 shared publications - Andrew John Coleman
Medical Physics Department, Guy’s and St Thomas’ NHS Foundation Trust, London
3 shared publications F. Al-Niaimi
Dermatological Surgery & Laser Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, SE1 7EH, U.K.
3 shared publicationsR. Patalay
Dermatological Surgery & Laser Unit St John's Institute of Dermatology Guy's & St Thomas' NHS Foundation Trust London UK
3 shared publicationsA. Robson
Guy's and St Thomas' NHS Foundation Trust, St John's Institute of Dermatology, London, U.K.
2 shared publications
Latest Publications
- Open Access
- 18 March 2026
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 6 (3) , 313-317
Cartilage calcification of the ears secondary to adrenal insufficiency
Calcification of the auricular cartilage is a rare condition, associated with either local or systemic causes. Among systemic causes, endocrine disorders, particularly adrenal insufficiency, are the most frequently reported. A 41-year-old man presented with a 1-year history of stiffness and pain in both ears. The ears became swollen and erythematous and, over time, they became painful to touch or move. Physical examination revealed rigid, immobile auricles. Biopsy, X-ray and computed tomography (CT) confirmed cartilage calcification. Laboratory tests showed markedly low cortisol and adrenocorticotropic hormone levels, leading to the diagnosis of secondary adrenal insufficiency. Auricular cartilage calcification is a rare but significant manifestation of adrenal insufficiency. Skull X-rays, noncontrast CT and laboratory tests are essential for diagnosis. No effective treatment currently exists to reverse calcification. Early recognition and hormone replacement therapy can prevent further progression.
- 18 March 2026
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 6 (3) , 313-317
Open AccessCartilage calcification of the ears secondary to adrenal insufficiency
Calcification of the auricular cartilage is a rare condition, associated with either local or systemic causes. Among systemic causes, endocrine disorders, particularly adrenal insufficiency, are the most frequently reported. A 41-year-old man presented with a 1-year history of stiffness and pain in both ears. The ears became swollen and erythematous and, over time, they became painful to touch or move. Physical examination revealed rigid, immobile auricles. Biopsy, X-ray and computed tomography (CT) confirmed cartilage calcification. Laboratory tests showed markedly low cortisol and adrenocorticotropic hormone levels, leading to the diagnosis of secondary adrenal insufficiency. Auricular cartilage calcification is a rare but significant manifestation of adrenal insufficiency. Skull X-rays, noncontrast CT and laboratory tests are essential for diagnosis. No effective treatment currently exists to reverse calcification. Early recognition and hormone replacement therapy can prevent further progression.
- 27 June 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (Supplement)
DS28 Left-handedness in dermatological surgery
Overall, 90% of the world’s population are right-hand dominant (RHD) and as such most environments are designed with right-handed individuals in mind. This extends to operating theatres, where left-hand dominant (LHD) surgeons face documented challenges when training in right-handed environments. These challenges include limited access to left-handed instruments and a lack of LHD mentors. When using right-handed instruments, LHD surgeons must reverse their natural motion or learn to operate with their right hand – both of which are unnatural and fatiguing. This study aims to explore the experiences, challenges and adaptations of left-handed dermatologists, trainees, and general practitioners with extended roles (GPwERs) in Ireland and the UK when performing dermatological surgery. An online questionnaire was distributed to dermatologists, trainees, GPwERs and specialist nurses through Irish and UK dermatology professional organizations. In total 105 respondents participated (50 consultants, 35 trainees, four GPwERs and 16 nurses). Of these, 47 (44.8%) were LHD and 58 (55.2%) were RHD. Five of 15 (33%) Mohs surgeons were LHD. Among 47 LHD respondents, 13 reported operating equally with both hands, 31 with primarily the left hand, and three with primarily the right hand. Only 6% (n = 3) of LHD respondents have access to left-handed instruments, although only 10 respondents had requested them: two successfully and eight unsuccessfully. Eighteen LHD respondents had tried to change handedness during their training. When comparing handedness across surgical tasks, LHD trainees were more likely than RHD trainees to report using their nondominant hand or demonstrating ambidexterity when using scissors (47% vs. 7%), suturing (38% vs. 5%) and undermining (34% vs. 14%). No difference was found in electrocautery (9% vs. 10%) or scalpel use (9% vs. 5%). When asked whether hand dominance significantly affected the learning curve in dermatological surgery, 53% (25 of 47) of LHD respondents felt it did not, compared with 22% (13 of 58) of RHD respondents, although previous research has shown increased efficiency using handed-matched vs. handed-unmatched needle drivers. Themes from open-ended questions highlighted initial difficulties with scissors and needle holders, but all reported adaptation. Some respondents noted logistical challenges in acquiring and maintaining left-handed equipment within departments, and many indicated they were self-taught, struggling to find adequate resources for left-handed surgical training techniques. This study highlights challenges faced by LHD dermatologists, trainees and GPwERs, particularly due to limited access to left-handed instruments and training resources. While most respondents did not feel their handedness significantly affected their learning curve, the lack of appropriate tools and mentorship remains a barrier. Improving access to left-handed instruments and tailored training could enhance the learning experience and reduce the physical strain on LHD practitioners in dermatological surgery.
- 27 June 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (Supplement)
DS28 Left-handedness in dermatological surgery
Overall, 90% of the world’s population are right-hand dominant (RHD) and as such most environments are designed with right-handed individuals in mind. This extends to operating theatres, where left-hand dominant (LHD) surgeons face documented challenges when training in right-handed environments. These challenges include limited access to left-handed instruments and a lack of LHD mentors. When using right-handed instruments, LHD surgeons must reverse their natural motion or learn to operate with their right hand – both of which are unnatural and fatiguing. This study aims to explore the experiences, challenges and adaptations of left-handed dermatologists, trainees, and general practitioners with extended roles (GPwERs) in Ireland and the UK when performing dermatological surgery. An online questionnaire was distributed to dermatologists, trainees, GPwERs and specialist nurses through Irish and UK dermatology professional organizations. In total 105 respondents participated (50 consultants, 35 trainees, four GPwERs and 16 nurses). Of these, 47 (44.8%) were LHD and 58 (55.2%) were RHD. Five of 15 (33%) Mohs surgeons were LHD. Among 47 LHD respondents, 13 reported operating equally with both hands, 31 with primarily the left hand, and three with primarily the right hand. Only 6% (n = 3) of LHD respondents have access to left-handed instruments, although only 10 respondents had requested them: two successfully and eight unsuccessfully. Eighteen LHD respondents had tried to change handedness during their training. When comparing handedness across surgical tasks, LHD trainees were more likely than RHD trainees to report using their nondominant hand or demonstrating ambidexterity when using scissors (47% vs. 7%), suturing (38% vs. 5%) and undermining (34% vs. 14%). No difference was found in electrocautery (9% vs. 10%) or scalpel use (9% vs. 5%). When asked whether hand dominance significantly affected the learning curve in dermatological surgery, 53% (25 of 47) of LHD respondents felt it did not, compared with 22% (13 of 58) of RHD respondents, although previous research has shown increased efficiency using handed-matched vs. handed-unmatched needle drivers. Themes from open-ended questions highlighted initial difficulties with scissors and needle holders, but all reported adaptation. Some respondents noted logistical challenges in acquiring and maintaining left-handed equipment within departments, and many indicated they were self-taught, struggling to find adequate resources for left-handed surgical training techniques. This study highlights challenges faced by LHD dermatologists, trainees and GPwERs, particularly due to limited access to left-handed instruments and training resources. While most respondents did not feel their handedness significantly affected their learning curve, the lack of appropriate tools and mentorship remains a barrier. Improving access to left-handed instruments and tailored training could enhance the learning experience and reduce the physical strain on LHD practitioners in dermatological surgery.
- Open Access
- 29 April 2025
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 5 (3) , 241-244
A survey of how frequently UK-based dermatology clinicians apply sun protection factor and the variables influencing this
This study evaluates sunscreen application practices among UK dermatology clinicians, revealing that only 10% meet recommended reapplication guidelines. Factors such as skin type, gender, product preferences and topical treatments significantly influence sun protection factor (SPF) use. Findings underscore the need for clearer clinical guidelines and practical solutions to enhance adherence and inform patient education.
- 29 April 2025
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 5 (3) , 241-244
Open AccessA survey of how frequently UK-based dermatology clinicians apply sun protection factor and the variables influencing this
This study evaluates sunscreen application practices among UK dermatology clinicians, revealing that only 10% meet recommended reapplication guidelines. Factors such as skin type, gender, product preferences and topical treatments significantly influence sun protection factor (SPF) use. Findings underscore the need for clearer clinical guidelines and practical solutions to enhance adherence and inform patient education.
- Open Access
- 1 December 2023
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (12) , 5044-5059
Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression
Xeroderma pigmentosum (XP) results from biallelic mutations in any of eight genes involved in DNA repair systems, thus defining eight different genotypes (XPA, XPB, XPC, XPD, XPE, XPF, XPG and XP variant or XPV). In addition to cutaneous and ophthalmological features, some patients present with XP neurological disease. It is unknown whether the different neurological signs and their progression differ among groups. Therefore, we aim to characterize the XP neurological disease and its evolution in the heterogeneous UK XP cohort. Patients with XP were followed in the UK National XP Service, from 2009 to 2021. Age of onset for different events was recorded. Cerebellar ataxia and additional neurological signs and symptoms were rated with the Scale for the Assessment and Rating of Ataxia (SARA), the Inventory of Non-Ataxia Signs (INAS) and the Activities of Daily Living questionnaire (ADL). Patients’ mutations received scores based on their predicted effects. Data from available ancillary tests were collected. Ninety-three XP patients were recruited. Thirty-six (38.7%) reported neurological symptoms, especially in the XPA, XPD and XPG groups, with early-onset and late-onset forms, and typically appearing after cutaneous and ophthalmological symptoms. XPA, XPD and XPG patients showed higher SARA scores compared to XPC, XPE and XPV. SARA total scores significantly increased over time in XPD (0.91 points/year, 95% confidence interval: 0.61, 1.21) and XPA (0.63 points/year, 95% confidence interval: 0.38, 0.89). Hyporeflexia, hypopallesthaesia, upper motor neuron signs, chorea, dystonia, oculomotor signs and cognitive impairment were frequent findings in XPA, XPD and XPG. Cerebellar and global brain atrophy, axonal sensory and sensorimotor neuropathies, and sensorineural hearing loss were common findings in patients. Some XPC, XPE and XPV cases presented with abnormalities on examination and/or ancillary tests, suggesting underlying neurological involvement. More severe mutations were associated with a faster progression in SARA total score in XPA (0.40 points/year per 1-unit increase in severity score) and XPD (0.60 points/year per 1-unit increase), and in ADL total score in XPA (0.35 points/year per 1-unit increase). Symptomatic and asymptomatic forms of neurological disease are frequent in XP patients, and neurological symptoms can be an important cause of disability. Typically, the neurological disease will be preceded by cutaneous and ophthalmological features, and these should be actively searched in patients with idiopathic late-onset neurological syndromes. Scales assessing cerebellar function, especially walking and speech, and disability can show progression in some of the groups. Mutation severity can be used as a prognostic biomarker for stratification purposes in clinical trials.
- 1 December 2023
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (12) , 5044-5059
Open AccessNeurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression
Xeroderma pigmentosum (XP) results from biallelic mutations in any of eight genes involved in DNA repair systems, thus defining eight different genotypes (XPA, XPB, XPC, XPD, XPE, XPF, XPG and XP variant or XPV). In addition to cutaneous and ophthalmological features, some patients present with XP neurological disease. It is unknown whether the different neurological signs and their progression differ among groups. Therefore, we aim to characterize the XP neurological disease and its evolution in the heterogeneous UK XP cohort. Patients with XP were followed in the UK National XP Service, from 2009 to 2021. Age of onset for different events was recorded. Cerebellar ataxia and additional neurological signs and symptoms were rated with the Scale for the Assessment and Rating of Ataxia (SARA), the Inventory of Non-Ataxia Signs (INAS) and the Activities of Daily Living questionnaire (ADL). Patients’ mutations received scores based on their predicted effects. Data from available ancillary tests were collected. Ninety-three XP patients were recruited. Thirty-six (38.7%) reported neurological symptoms, especially in the XPA, XPD and XPG groups, with early-onset and late-onset forms, and typically appearing after cutaneous and ophthalmological symptoms. XPA, XPD and XPG patients showed higher SARA scores compared to XPC, XPE and XPV. SARA total scores significantly increased over time in XPD (0.91 points/year, 95% confidence interval: 0.61, 1.21) and XPA (0.63 points/year, 95% confidence interval: 0.38, 0.89). Hyporeflexia, hypopallesthaesia, upper motor neuron signs, chorea, dystonia, oculomotor signs and cognitive impairment were frequent findings in XPA, XPD and XPG. Cerebellar and global brain atrophy, axonal sensory and sensorimotor neuropathies, and sensorineural hearing loss were common findings in patients. Some XPC, XPE and XPV cases presented with abnormalities on examination and/or ancillary tests, suggesting underlying neurological involvement. More severe mutations were associated with a faster progression in SARA total score in XPA (0.40 points/year per 1-unit increase in severity score) and XPD (0.60 points/year per 1-unit increase), and in ADL total score in XPA (0.35 points/year per 1-unit increase). Symptomatic and asymptomatic forms of neurological disease are frequent in XP patients, and neurological symptoms can be an important cause of disability. Typically, the neurological disease will be preceded by cutaneous and ophthalmological features, and these should be actively searched in patients with idiopathic late-onset neurological syndromes. Scales assessing cerebellar function, especially walking and speech, and disability can show progression in some of the groups. Mutation severity can be used as a prognostic biomarker for stratification purposes in clinical trials.
- Open Access
- 14 February 2023
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 48 (7) , 778-780
Mohs micrographic surgery for the treatment of primary cutaneous mucinous carcinoma
Primary cutaneous mucinous carcinoma (PCMC) is a rare adnexal tumour of the skin. Clinically, it appears as a benign cyst, but it has characteristic histopathology. It is a slow-growing tumour that rarely metastasizes but is associated with significant morbidity due to its high recurrence rate. Standard practice has been to surgically remove it with a wide local excision of 1–2-cm margin. In the last decade, increasing reports of Mohs micrographic surgery (MMS) for the treatment of PCMC have been described. MMS appears to reduce recurrence rates while allowing for more conservative margins. Given the rarity of PCMC, there are no prospective randomized control trials on treatment. This is the largest case series of PCMC treated by MMS to date.
- 14 February 2023
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 48 (7) , 778-780
Open AccessMohs micrographic surgery for the treatment of primary cutaneous mucinous carcinoma
Primary cutaneous mucinous carcinoma (PCMC) is a rare adnexal tumour of the skin. Clinically, it appears as a benign cyst, but it has characteristic histopathology. It is a slow-growing tumour that rarely metastasizes but is associated with significant morbidity due to its high recurrence rate. Standard practice has been to surgically remove it with a wide local excision of 1–2-cm margin. In the last decade, increasing reports of Mohs micrographic surgery (MMS) for the treatment of PCMC have been described. MMS appears to reduce recurrence rates while allowing for more conservative margins. Given the rarity of PCMC, there are no prospective randomized control trials on treatment. This is the largest case series of PCMC treated by MMS to date.
- 16 December 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (1) , e4
Treatment of multiple facial basal cell carcinomas in a child with xeroderma pigmentosum complementation group C with Mohs micrographic surgery
- 16 December 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (1) , e4
Treatment of multiple facial basal cell carcinomas in a child with xeroderma pigmentosum complementation group C with Mohs micrographic surgery
- 11 November 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (1) , 233-236
Dermatofibrosarcoma protuberans (DFSP) in children: A combined multidisciplinary approach
Dermatofibrosarcoma protuberans (DFSP) is rare, comprising (1%‐6%) of all sarcomas. The incidence is less than one per million before the age of 20. It is a locally aggressive tumor with a low risk of metastasis. We share our experience in the management of three pediatric patients with complex cases of DFSP in a combined surgical approach involving plastic and dermatologic surgery, using the slow Mohs micrographic surgery technique.
- 11 November 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (1) , 233-236
Dermatofibrosarcoma protuberans (DFSP) in children: A combined multidisciplinary approach
Dermatofibrosarcoma protuberans (DFSP) is rare, comprising (1%‐6%) of all sarcomas. The incidence is less than one per million before the age of 20. It is a locally aggressive tumor with a low risk of metastasis. We share our experience in the management of three pediatric patients with complex cases of DFSP in a combined surgical approach involving plastic and dermatologic surgery, using the slow Mohs micrographic surgery technique.
- Open Access
- 16 August 2020
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (1) , 179-180
Patient perceptions of Mohs micrographic surgery during the COVID‐19 pandemic and lessons for the next outbreak
Understanding patient experiences of healthcare systems during the pandemic is important to help strategize for future similar events. We operated a reduced Mohs micrographic surgery (MMS) service during the pandemic through rationalising patients by tumour type, age, co‐morbidities and patient choice. We sought to establish patient expectations and concerns of attending MMS by conducting a survey of those attending surgery over a 7‐week period from 24th April 2020. The results are particularly relevant when re‐establishing services in preparation for an expected upsurge of routine activity (including surgical procedures) or ‘second spike’ of COVID‐19 cases later this year.
- 16 August 2020
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (1) , 179-180
Open AccessPatient perceptions of Mohs micrographic surgery during the COVID‐19 pandemic and lessons for the next outbreak
Understanding patient experiences of healthcare systems during the pandemic is important to help strategize for future similar events. We operated a reduced Mohs micrographic surgery (MMS) service during the pandemic through rationalising patients by tumour type, age, co‐morbidities and patient choice. We sought to establish patient expectations and concerns of attending MMS by conducting a survey of those attending surgery over a 7‐week period from 24th April 2020. The results are particularly relevant when re‐establishing services in preparation for an expected upsurge of routine activity (including surgical procedures) or ‘second spike’ of COVID‐19 cases later this year.
- 29 June 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (4) , 731-739
A 10‐year review of surgical management of dermatofibrosarcoma protuberans*
Background Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer. Standard treatment in the United Kingdom (UK) is either surgical wide local excision (WLE) or Mohs micrographic surgery (MMS). It is unclear which approach has the lower recurrence rate. Objectives We undertook a retrospective comparative review of DFSP surgical management in the UK National Health Service (NHS) in order to define: current surgical practice for primary and recurrent DFSP local recurrence rates for primary DFSP survival outcomes for DFSP. Methods Retrospective clinical case‐note review of patients with histologically‐confirmed DFSP (January 2004–2014) who have undergone surgical treatment. Results Surgical management of 483 primary and 64 recurrent DFSP in 11 plastic surgery and 15 dermatology departments was analysed. Almost 75% of primary DFSP (n=362) were treated with WLE and 20.1% (n=97) with MMS. For recurrent DFSP, 68.7% (n=44) and 23.4% (n=15) underwent WLE and MMS, respectively. Recurrent primary DFSP occurred in 6 patients after WLE and none after MMS. Median follow‐up was 4.8 years [IQR 3.5, 5.8] with 8 reported deaths during the follow‐up analysis period; one confirmed to be DFSP‐related. Conclusions WLE was the commonest surgical modality used to treat DFSP across the UK. The local recurrence rate was very low, occurring only after WLE. Although a prospective RCT may provide more definitive outcomes, in the absence of a clearly superior surgical modality, treatment decisions should be based on patient preference, clinical expertise and cost.
- 29 June 2020
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 184 (4) , 731-739
A 10‐year review of surgical management of dermatofibrosarcoma protuberans*
Background Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer. Standard treatment in the United Kingdom (UK) is either surgical wide local excision (WLE) or Mohs micrographic surgery (MMS). It is unclear which approach has the lower recurrence rate. Objectives We undertook a retrospective comparative review of DFSP surgical management in the UK National Health Service (NHS) in order to define: current surgical practice for primary and recurrent DFSP local recurrence rates for primary DFSP survival outcomes for DFSP. Methods Retrospective clinical case‐note review of patients with histologically‐confirmed DFSP (January 2004–2014) who have undergone surgical treatment. Results Surgical management of 483 primary and 64 recurrent DFSP in 11 plastic surgery and 15 dermatology departments was analysed. Almost 75% of primary DFSP (n=362) were treated with WLE and 20.1% (n=97) with MMS. For recurrent DFSP, 68.7% (n=44) and 23.4% (n=15) underwent WLE and MMS, respectively. Recurrent primary DFSP occurred in 6 patients after WLE and none after MMS. Median follow‐up was 4.8 years [IQR 3.5, 5.8] with 8 reported deaths during the follow‐up analysis period; one confirmed to be DFSP‐related. Conclusions WLE was the commonest surgical modality used to treat DFSP across the UK. The local recurrence rate was very low, occurring only after WLE. Although a prospective RCT may provide more definitive outcomes, in the absence of a clearly superior surgical modality, treatment decisions should be based on patient preference, clinical expertise and cost.
- Open Access
- 23 October 2019
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 5 (5) , a004408
Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease
“Mutational signatures” are patterns of mutations that report DNA damage and subsequent repair processes that have occurred. Whole-genome sequencing (WGS) can provide additional information to standard diagnostic techniques and can identify therapeutic targets. A 32-yr-old male with xeroderma pigmentosum developed metastatic angiosarcoma that was unresponsive to three lines of conventional sarcoma therapies. WGS was performed on his primary cancer revealing a hypermutated tumor, including clonal ultraviolet radiation-induced mutational patterns (Signature 7) and subclonal signatures of mutated DNA polymerase epsilon (POLE) (Signature 10). These signatures are associated with response to immune checkpoint blockade. Immunohistochemistry confirmed high PD-L1 expression in metastatic deposits. The anti-PD-1 monoclonal antibody pembrolizumab was commenced off-label given the POLE mutation and high mutational load. After four cycles, there was a significant reduction in his disease with almost complete resolution of the metastatic deposits. This case highlights the importance of WGS in the analysis, interpretation, and treatment of cancers. We anticipate that as WGS becomes integral to the cancer diagnostic pathway, treatments will be stratified to the individual based on their unique genomic and/or transcriptomic profile, enhancing classical approaches of histologically driven treatment decisions.
- 23 October 2019
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Molecular Case Studies
- Vol. 5 (5) , a004408
Open AccessDramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease
“Mutational signatures” are patterns of mutations that report DNA damage and subsequent repair processes that have occurred. Whole-genome sequencing (WGS) can provide additional information to standard diagnostic techniques and can identify therapeutic targets. A 32-yr-old male with xeroderma pigmentosum developed metastatic angiosarcoma that was unresponsive to three lines of conventional sarcoma therapies. WGS was performed on his primary cancer revealing a hypermutated tumor, including clonal ultraviolet radiation-induced mutational patterns (Signature 7) and subclonal signatures of mutated DNA polymerase epsilon (POLE) (Signature 10). These signatures are associated with response to immune checkpoint blockade. Immunohistochemistry confirmed high PD-L1 expression in metastatic deposits. The anti-PD-1 monoclonal antibody pembrolizumab was commenced off-label given the POLE mutation and high mutational load. After four cycles, there was a significant reduction in his disease with almost complete resolution of the metastatic deposits. This case highlights the importance of WGS in the analysis, interpretation, and treatment of cancers. We anticipate that as WGS becomes integral to the cancer diagnostic pathway, treatments will be stratified to the individual based on their unique genomic and/or transcriptomic profile, enhancing classical approaches of histologically driven treatment decisions.